Cardiol Rev. 2026 Jul 2. doi: 10.1097/CRD.0000000000001385. Online ahead of print.
ABSTRACT
Atherosclerosis is a progressive inflammatory process involving the arteries of the body that is driven by cumulative exposure to low-density lipoprotein cholesterol and other lipoprotein particles. Although clinical manifestations typically occur later in life, the atherosclerotic process can begin decades earlier if lipid levels are not well controlled. Despite this, current prevention strategies do not adequately account for young adults at elevated lifetime cardiovascular risk. This review examined multiple studies evaluating statin use in young adults and found that many high-risk individuals are not identified or treated under current approaches. The studies demonstrate that 2013 and 2018 American College of Cardiology and American Heart Association guidelines excluded a substantial proportion of young adults who experienced myocardial infarction and may have benefited from therapy prior to their event. In addition to this, statin therapy remains underutilized even in individuals who meet guideline-based criteria. Recent guideline updates in 2026 have emphasized cumulative lifetime exposure to atherogenic lipoproteins and expanded consideration of statin therapy to younger populations, reflecting an important shift toward earlier identification and prevention of cardiovascular risk. This review examines contemporary evidence regarding statin therapy in young adults, identifies barriers to treatment, and discusses potential strategies to improve early cardiovascular prevention.
PMID:42383793 | DOI:10.1097/CRD.0000000000001385